Mircescu Gabriel, Garneata Liliana, Florea Laura, Cepoi Vasile, Capsa Dimitrie, Covic Maria, Gherman-Caprioara Mirela, Gluhovschi Gheorghe, Golea Ovidiu Sorin, Barbulescu Carmen, Rus Elvira, Santimbrean Caterina, Mardare Nicoleta, Covic Adrian
Dr Carol Davila Teaching Hospital of Nephrology, Bucharest, Romania.
Perit Dial Int. 2006 Mar-Apr;26(2):266-75.
This report describes the status of renal replacement therapy (RRT), particularly continuous ambulatory peritoneal dialysis (CAPD), in Romania (a country with previously limited facilities), outlines the fast development rate of CAPD, and presents national changes in a European context.
Trends in the development of RRT were analyzed in 2003 on a national basis using annual center questionnaires from 1995 to 2003. Survival data and prognostic risk factors were calculated retrospectively from a representative sample of 2284 patients starting RRT between 1 January 1995 and 31 December 2001 (44% of the total RRT population investigated).
The annual rate of increase in the number of RRT patients (11%) was supported mainly by an exponential development of the CAPD population (+600%); the hemodialysis (HD) growth rate was stable (+33%) and renal transplantation had a marginal contribution. The characteristics of both HD and PD incident patients changed according to current European epidemiology (increasing age and prevalence of diabetes and nephroangiosclerosis). There were significant differences between PD and HD incident populations, PD patients being significantly older and having a higher prevalence of diabetic nephropathy and baseline comorbidities, probably reflecting different inclusion policies. The estimated overall survival of RRT patients in Romania was 90.6% at 1 year [confidence interval (CI) 89.4 - 91.8] and 62.2% at 5 years (CI 59.4 - 65.0). The initial treatment modality did not significantly influence patients' survival. There was no difference in unadjusted technique survival during the first 2 years; afterwards, there was a clear advantage for HD, with more patients being transferred from PD to HD. Several factors seemed to significantly and negatively influence PD patients' survival (Cox regression analysis): male gender, lack of predialysis erythropoietin treatment, and initial comorbidities. Stratified analysis to discover the influence of these factors on patients' survival revealed that HD was associated with an increased risk of death in the younger nondiabetic end-stage renal disease population, regardless of other coexisting comorbid conditions. However, in older patients (>65 years) and in diabetics, regardless of the presence or absence of associated comorbid conditions, there was no significant difference in death rates between HD and PD patients.
We report an impressive quantitative and qualitative development of CAPD in one of the rapidly growing Central and Eastern Europe countries. CAPD should be the method of choice for young nondiabetic end-stage renal disease patients. Improvement in predialysis nephrologic care and in transplantation rates is required to further ensure the ultimate success of the Romanian PD program.
本报告描述了罗马尼亚(一个此前设施有限的国家)肾脏替代治疗(RRT)的现状,尤其是持续性非卧床腹膜透析(CAPD),概述了CAPD的快速发展速度,并呈现了在欧洲背景下该国的变化情况。
2003年,利用1995年至2003年各中心的年度调查问卷,在全国范围内分析了RRT的发展趋势。回顾性计算了1995年1月1日至2001年12月31日开始接受RRT治疗的2284例患者(占所调查的RRT患者总数的44%)这一代表性样本的生存数据和预后风险因素。
RRT患者数量的年增长率(11%)主要得益于CAPD人群的指数式增长(+600%);血液透析(HD)的增长率稳定(+33%),肾移植的贡献微乎其微。HD和PD新发病例的特征均符合当前欧洲的流行病学情况(年龄增加、糖尿病和肾血管硬化患病率上升)。PD和HD新发病例人群之间存在显著差异,PD患者年龄显著更大,糖尿病肾病和基线合并症的患病率更高,这可能反映了不同的纳入政策。罗马尼亚RRT患者的估计1年总生存率为90.6%[置信区间(CI)89.4 - 91.8],5年总生存率为62.2%(CI 59.4 - 65.0)。初始治疗方式对患者生存没有显著影响。前两年未调整的技术生存率没有差异;此后,HD有明显优势,更多患者从PD转为HD。几个因素似乎对PD患者的生存有显著的负面影响(Cox回归分析):男性、透析前未接受促红细胞生成素治疗以及初始合并症。分层分析这些因素对患者生存的影响发现,在年轻的非糖尿病终末期肾病患者中,HD与死亡风险增加相关,无论是否存在其他合并症。然而,在老年患者(>65岁)和糖尿病患者中,无论是否存在相关合并症,HD和PD患者的死亡率没有显著差异。
我们报告了在中东欧快速发展的国家之一,CAPD在数量和质量上都取得了令人瞩目的发展。CAPD应成为年轻非糖尿病终末期肾病患者的首选治疗方法。需要改善透析前的肾脏护理和提高移植率,以进一步确保罗马尼亚PD项目的最终成功。